Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global ...

Key market opportunities include the rising prevalence of chronic diseases and increased regulatory approvals driving demand ...

Vector BioMed raised $15 million in a first round of funding as the startup looks to help fill a big gap in the manufacture of cell and gene therapies. The latest entry into the CDMO viral vector ...

Oxford, UK – 4 February 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces ...

Vector Biolabs, a custom design and manufacturing service provider for AAV and adenovirus viral vectors announced the completion of a facility expansion to meet growing demand. The purpose of the ...

A global contract developer says it is among the first to offer a standardized approach to manufacturing adeno-associated viruses (AAVs) and lentiviruses (LVVs) for advanced therapies. AGC Biologics ...

Demand for adeno-associated viral (AAV) vectors is increasing as more and more cell and gene therapy firms use them to make products. In response, vector suppliers are embracing faster, more efficient ...

A lack of global capacity to produce cell and gene therapies has been exacerbated by an even more pressing need: to develop and manufacture coronavirus vaccines. So it appears the timing is right for ...

DUBLIN, March 23, 2021 /PRNewswire/ -- The "Viral Vector Manufacturing - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Amid the COVID-19 crisis, the ...

Viral vectors are a key component of many advanced gene therapies and vaccines, but reliable, large-scale manufacturing remains a significant challenge. Continued innovation in vector design, cell ...

MALVERN, Pa.--(BUSINESS WIRE)--Vector Biolabs, a custom design and manufacturing service provider for AAV and adenovirus viral vectors announced the completion of a facility expansion to meet growing ...